Gilead Sciences Inc (GILD)

73.74
0.65 0.87
NASDAQ : Health Care
Prev Close 74.39
Open 74.65
Day Low/High 73.62 / 75.29
52 Wk Low/High 77.92 / 120.37
Volume 8.91M
Avg Volume 8.65M
Exchange NASDAQ
Shares Outstanding 1.31B
Market Cap 96.38B
EPS 10.10
P/E Ratio 7.80
Div & Yield 2.08 (2.80%)

Latest News

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

The Worm Has Turned in Biotech's Favor

The Worm Has Turned in Biotech's Favor

However, it will take acquisition activity to heat up again for the sector to rally in a big way.

Stocks Are Guilty by Association: Cramer's 'Mad Money' Recap (Thursday 7/20/17)

Stocks Are Guilty by Association: Cramer's 'Mad Money' Recap (Thursday 7/20/17)

Jim Cramer says these market rotations are crushing good stocks that don't deserve it.

Try This Bullish Diagonal Spread on Gilead Sciences

We want to take advantage of the skew on the August and September calls and support our bullish thesis.

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

European Medicines Agency Validates Gilead's Marketing Application For Fixed-Dose Combination Of Bictegravir, Emtricitabine And Tenofovir Alafenamide For Treatment Of HIV

European Medicines Agency Validates Gilead's Marketing Application For Fixed-Dose Combination Of Bictegravir, Emtricitabine And Tenofovir Alafenamide For Treatment Of HIV

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Marketing Authorization Application (MAA) for an investigational, once-daily single tablet regimen containing bictegravir (50 mg; BIC), a novel...

Gilead Sciences To Release Second Quarter 2017 Financial Results On Wednesday, July 26, 2017

Gilead Sciences To Release Second Quarter 2017 Financial Results On Wednesday, July 26, 2017

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2017 financial results will be released on Wednesday, July 26, after the market closes.

3 Red-Hot Biotech Stocks That Could Get Even Hotter

3 Red-Hot Biotech Stocks That Could Get Even Hotter

An analyst weighs in.

This $156 Billion Hedge Fund 'Hate List' Is Dead Wrong About These Stocks

This $156 Billion Hedge Fund 'Hate List' Is Dead Wrong About These Stocks

There's reason to believe they got one wrong.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

If Hedge Funds Are Selling These 3 Huge Stocks - Should You?

If Hedge Funds Are Selling These 3 Huge Stocks - Should You?

The pros hate these three big names, but there's reason to believe they got one wrong.

Another Steep Selloff in Tech Stocks Wipes Out Nasdaq's June Gains

Another Steep Selloff in Tech Stocks Wipes Out Nasdaq's June Gains

A tech selloff yields big Wall Street losses.

Bonds May Face a Correction Soon

With dull action in the equities market, attention is focusing on bonds.

These Stocks Are Changing Course

These Stocks Are Changing Course

Bullish and bearish reversals for this week.

Is Gilead Sciences on the Verge of a Powerful Rally?

Is Gilead Sciences on the Verge of a Powerful Rally?

Time for this one to pop.

Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout

Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout

The stock has been on fire.

2 Recovering Biotech Names With Room to Run

2 Recovering Biotech Names With Room to Run

There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.

European CHMP Adopts Positive Opinion For Gilead's Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Chronic Hepatitis C Genotypes

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the...

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare leads markets after the release of the Senate health plan.

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Healthcare leads markets after the release of the Senate health plan.

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare leads markets after Senate bill's release.

Cramer: Today's Market Emotion - Group Hug!

Cramer: Today's Market Emotion - Group Hug!

Banks, tech and healthcare are all seeing renewed buying.

All the Rallying Big Bank Stocks Look Very Risky, Doug Kass Says

All the Rallying Big Bank Stocks Look Very Risky, Doug Kass Says

Doug Kass shares his thoughts on Apple, Google and Starbucks.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat